What T3a Means
Invasion through muscularis propria into perivesical fat but not beyond.
Treatment Approach for T3a
Neoadjuvant chemotherapy (cisplatin-based doublet) mandatory. Radical cystectomy with extended pelvic lymph node dissection. Checkpoint inhibitor immunotherapy increasingly used for unresectable disease.
Survival Rates and Prognosis
The 5-year survival rate for bladder cancer at T3a is approximately 5-year: 30-45%. Survival rates are statistical averages drawn from large patient populations and may not reflect your individual outcome. Factors that influence your specific prognosis include your age, overall health, tumour biology, and how well the cancer responds to treatment.
Important: These numbers are drawn from historical data. Newer treatments available today may improve outcomes beyond what published statistics show. Discuss your individual prognosis with your oncologist.
How Other Stages Compare
| Stage | 5-Year Survival | Treatment |
|---|---|---|
| Ta | 5-year: 88-95% | TURBT + intravesical therapy (BCG or mitomycin C). Lifelong surveillance… |
| Tis | 5-year: 60-85% with BCG treatment | TURBT + BCG induction (6 weekly instillations). Maintenance BCG recommended… |
| T1 | 5-year: 70-80% | TURBT + re-TURBT at 3-4 weeks to ensure complete resection and assess response…. |
| T2a | 5-year: 50-60% | Standard: neoadjuvant chemotherapy (gemcitabine-cisplatin or MVAC) followed by… |
| T2b | 5-year: 40-55% | Neoadjuvant gemcitabine-cisplatin (preferred) or MVAC followed by radical… |
| T3b | 5-year: 25-35% | Neoadjuvant chemotherapy followed by en bloc resection of involved organs…. |
| T4a | 5-year: 15-25% | Neoadjuvant chemotherapy mandatory but disease likely unresectable. Palliative… |
| T4b | 5-year: <10% | Unresectable disease. Palliative chemotherapy (gemcitabine-cisplatin if fit) or… |
| N0 | Favorable prognostic marker | Enables consideration of bladder-preserving approaches in T1-T2 disease. |
| N1 | 5-year: 35-50% | Neoadjuvant chemotherapy (cisplatin-based) + radical cystectomy with extended… |
| N2 | 5-year: 20-35% | Neoadjuvant chemotherapy essential. Radical cystectomy with extended pelvic and… |
| N3 | 5-year: <15% | Generally unresectable. Neoadjuvant chemotherapy often not tolerated…. |
| M0 | Favorable prognostic marker | Curative intent treatment (cystectomy + chemotherapy) considered. |
| M1a | 5-year: <10% | Palliative chemotherapy (gemcitabine-cisplatin or other platinum-based… |
| M1b | 5-year: <5% | Systemic palliative chemotherapy or immunotherapy. Radiation therapy for… |
Bladder Cancer Treatment in Top Cities
Diagnosed with T3a Bladder Cancer?
Our specialists can review your reports and create a personalised treatment plan.
Get a Free ConsultationAll Bladder Cancer stages Bladder Cancer overview
VICI Healthcare is for informational purposes only and does not replace professional medical advice. Always consult a qualified oncologist.